Actavia Life Sciences Incの収益はセグメントまたは地域別にどのように分けられていますか?
Actavia Life Sciences Incは収益を上げていますか?
Actavia Life Sciences Incに負債はありますか?
Actavia Life Sciences Incの発行済株式数は何株ですか?
主要データ
前終値
$0.0005
始値
$0.0004
当日レンジ
$0.0004 - $0.0005
52週レンジ
$0.0004 - $0.004
取引高
20
平均取引高
327
1株当たり利益(TTM)
-0.00
配当利回り
--
時価総額
$385.9K
RASPとは何ですか?
Actavia Life Sciences, Inc. is a biotechnology company, which engages in the development of therapeutics for the treatment of leukemia and lymphoma diseases. The company is headquartered in New York City, New York and currently employs 1 full-time employees. The company went IPO on 2014-03-28. The firm is engaged in developing therapeutics to address the unmet need that exists for acute myeloid leukemia (AML), and other forms of leukemia and lymphoma. AML is generally a disease of older adults. The company develops small molecule drug candidates targeting the LSD1 gene, which controls pathways underlying the etiology of AML subtypes. Its RASP-201 is a novel, orally dosed, selective reversible inhibitor of lysine specific demethylase (LSD1), a pathway that blocks differentiation and confers a poor prognosis to AML. RASP-201 when dosed orally shows in vivo therapeutic utility in murine (mouse) models of AML. Its primary indication is AML which may be fatal within weeks to months.